Corcept Therapeutics Incorporated Financial Statements (CORT)
|
|
|
|
Report date
|
|
|
15.02.2022 |
28.02.2023 |
15.02.2024 |
26.02.2025 |
24.02.2026 |
|
30.04.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
366.0 |
401.9 |
482.4 |
675.0 |
761.4 |
|
769.1 |
|
Operating Income, bln rub |
|
|
124.5 |
112.6 |
107.3 |
137.0 |
44.8 |
|
-8.22 |
|
EBITDA, bln rub |
? |
|
128.0 |
113.9 |
108.3 |
138.3 |
46.7 |
|
-6.79 |
|
Net profit, bln rub |
? |
|
112.5 |
101.4 |
106.1 |
139.7 |
99.7 |
|
47.9 |
|
|
OCF, bln rub |
? |
|
167.9 |
120.3 |
127.0 |
198.1 |
142.0 |
|
120.1 |
|
CAPEX, bln rub |
? |
|
0.469 |
0.413 |
0.139 |
2.17 |
0.211 |
|
0.308 |
|
FCF, bln rub |
? |
|
167.4 |
119.9 |
126.9 |
195.9 |
141.8 |
|
119.8 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
236.2 |
283.8 |
368.6 |
527.2 |
703.6 |
|
763.9 |
|
Cost of production, bln rub |
|
|
5.28 |
5.39 |
6.48 |
10.9 |
13.0 |
|
13.5 |
|
R&D, bln rub |
|
|
113.9 |
131.0 |
184.4 |
246.9 |
254.9 |
|
260.4 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
423.8 |
583.4 |
621.5 |
840.6 |
836.7 |
|
814.9 |
|
Net Assets, bln rub |
? |
|
375.8 |
501.8 |
506.7 |
679.6 |
647.8 |
|
638.0 |
|
Debt, bln rub |
|
|
0.526 |
1.14 |
0.151 |
6.94 |
6.11 |
|
9.64 |
|
Cash, bln rub |
|
|
223.5 |
431.7 |
368.2 |
383.3 |
372.2 |
|
338.2 |
|
Net debt, bln rub |
|
|
-223.0 |
-430.5 |
-368.1 |
-376.4 |
-366.0 |
|
-328.5 |
|
|
Ordinary share price, rub |
|
|
19.8 |
|
|
50.4 |
34.8 |
|
60.2 |
|
Number of ordinary shares, mln |
|
|
115.7 |
106.8 |
103.6 |
103.2 |
103.9 |
|
104.4 |
|
|
Market cap, bln rub |
|
|
2 290 |
0 |
0 |
5 202 |
3 614 |
|
6 289 |
|
EV, bln rub |
? |
|
2 067 |
-431 |
-368 |
4 825 |
3 248 |
|
5 961 |
|
Book value, bln rub |
|
|
376 |
502 |
507 |
680 |
648 |
|
638 |
|
|
EPS, rub |
? |
|
0.97 |
0.95 |
1.02 |
1.35 |
0.96 |
|
0.46 |
|
FCF/share, rub |
|
|
1.45 |
1.12 |
1.23 |
1.90 |
1.37 |
|
1.15 |
|
BV/share, rub |
|
|
3.25 |
4.70 |
4.89 |
6.58 |
6.24 |
|
6.11 |
|
|
EBITDA margin, % |
? |
|
35.0% |
28.3% |
22.5% |
20.5% |
6.13% |
|
-0.88% |
|
Net margin, % |
? |
|
30.7% |
25.2% |
22.0% |
20.7% |
13.1% |
|
6.23% |
|
FCF yield, % |
? |
|
7.31% |
|
|
3.77% |
3.92% |
|
1.90% |
|
ROE, % |
? |
|
29.9% |
20.2% |
20.9% |
20.6% |
15.4% |
|
7.51% |
|
ROA, % |
? |
|
26.6% |
17.4% |
17.1% |
16.6% |
11.9% |
|
5.88% |
|
|
P/E |
? |
|
20.4 |
0.00 |
0.00 |
37.2 |
36.3 |
|
131.3 |
|
P/FCF |
|
|
13.7 |
0.00 |
0.00 |
26.6 |
25.5 |
|
52.5 |
|
P/S |
? |
|
6.26 |
0.00 |
0.00 |
7.71 |
4.75 |
|
8.18 |
|
P/BV |
? |
|
6.09 |
0.00 |
0.00 |
7.65 |
5.58 |
|
9.86 |
|
EV/EBITDA |
? |
|
16.2 |
-3.78 |
-3.40 |
34.9 |
69.6 |
|
-877.6 |
|
Debt/EBITDA |
|
|
-1.74 |
-3.78 |
-3.40 |
-2.72 |
-7.84 |
|
48.4 |
|
|
R&D/CAPEX, % |
|
|
24 278% |
31 717% |
132 628% |
11 367% |
120 809% |
|
84 558% |
|
|
CAPEX/Revenue, % |
|
|
0.13% |
0.10% |
0.03% |
0.32% |
0.03% |
|
0.04% |
|
| Corcept Therapeutics Incorporated shareholders |
